Papers published on a yearly basis
Papers
More filters
McGill University1, New York University2, Mayo Clinic3, French Institute of Health and Medical Research4, Federal Institute for Drugs and Medical Devices5, University of New South Wales6, Rush University Medical Center7, University of California, Los Angeles8, Vancouver Hospital and Health Sciences Centre9, University of Pittsburgh10, Ludwig Maximilian University of Munich11, VU University Medical Center12, Women's College, Kolkata13, Case Western Reserve University14, Karolinska Institutet15
TL;DR: Mild cognitive impairment can be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension.
3,962 citations
TL;DR: This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
3,064 citations
TL;DR: In this article, the authors did a randomised trial to compare a policy of planned caesarean section with a plan of planned vaginal birth for selected breech-presentation pregnancies.
1,685 citations
TL;DR: Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply, and clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians.
Abstract: Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians. What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?
1,545 citations
TL;DR: Based on the available evidence, the Fugl-Meyer motor scale is recommended highly as a clinical and research tool for evaluating changes in motor impairment following stroke.
Abstract: Measurement of recovery after stroke is becoming increasingly important with the advent of new treatment options under investigation in stroke rehabilitation research. The Fugl-Meyer scale was developed as the first quantitative evaluative instrument for measuring sensorimotor stroke recovery, based on Twitchell and Brunnstrom’s concept of sequential stages of motor return in the hemiplegic stroke patient. The Fugl-Meyer is a well-designed, feasible and efficient clinical examination method that has been tested widely in the stroke population. Its primary value is the 100-point motor domain, which has received the most extensive evaluation. Excellent interrater and intrarater reliability and construct validity have been demonstrated, and preliminary evidence suggests that the Fugl-Meyer assessment is responsive to change. Limitations of the motor domain include a ceiling effect, omission of some potentially relevant items, and weighting of the arm more than the leg. Further study should test performance o...
1,520 citations
Authors
Showing all 4552 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Paul G. Richardson | 183 | 1533 | 155912 |
| Steven A. Narod | 134 | 970 | 84638 |
| Peter C. Austin | 112 | 657 | 60156 |
| Sandra E. Black | 104 | 681 | 51755 |
| Michael B. Yaffe | 102 | 379 | 41663 |
| Jeffrey S. Ginsberg | 101 | 343 | 37014 |
| Robert S. Kerbel | 101 | 360 | 43411 |
| Kathleen I. Pritchard | 96 | 534 | 55670 |
| Aditya K. Gupta | 86 | 695 | 26368 |
| Soo-Jin Park | 86 | 1282 | 37204 |
| Amiram Gafni | 85 | 575 | 31319 |
| Hiroo Imura | 83 | 781 | 29276 |
| Muhammad Mamdani | 83 | 441 | 28319 |
| Gillian A. Hawker | 82 | 309 | 35570 |
| Andrew R. Willan | 80 | 346 | 30215 |